Connect
MJA
MJA

Transfusion-dependent thalassaemia: a new era

Vasili Berdoukas and Bernadette Modell
Med J Aust 2008; 188 (2): 68-69.
Published online: 21 January 2008

With three iron chelating agents now available, management options have substantially increased

Outcomes in patients with thalassaemia major have been revolutionised over the past 50 years. Without transfusions, death usually occurred in the first decade of life. In the 1950s, transfusions were given to manage the symptoms of anaemia, which resulted in increased survival but significant morbidity. In the 1960s, regular blood transfusions were introduced to maintain relatively high mean haemoglobin levels in order to suppress the production of abnormal red cells in the bone marrow. This permitted good quality of life in childhood, but led to cardiac death from transfusional iron overload at a mean age of 18 years.1 Fortunately, the parenteral iron chelating agent desferrioxamine was also introduced in the 1960s, and its use to control iron load led to improved survival2 and reduced morbidity.3 Nevertheless, the difficult treatment regimen (subcutaneous infusion for 8–12 hours per night, 3–7 nights per week) resulted in poor compliance. Cardiomyopathy remains the most common cause of premature death in patients with thalassaemia,3 even in well chelated patients.4

  • Vasili Berdoukas1
  • Bernadette Modell2

  • 1 Department of Medicine, Lefkos Stavros Hospital, Athens, Attika, Greece.
  • 2 Centre for Health Informatics and Multiprofessional Education, University College London, London, UK.

Correspondence: plomari@hol.gr

Competing interests:

Vasili Berdoukas is a consultant for ApoPharma, the company that markets deferiprone, and he has a confidentiality agreement with Novartis for the development of deferasirox. He has also received travel assistance and honoraria for attending conferences and for presentations at such conferences.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.